Healio

Ublituximab demonstrates sustained benefit for relapsing MS in interim open-label analysis

Among adults with relapsing MS who received ublituximab, the annualized relapse rate continued to drop with up to 5 years of ...
ascopubs.org

A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC).

SALVOVAR: A pragmatic randomized phase III trial comparing the salvage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic ovarian cancers (GINECO-OV130b; ENGOT ...
Medscape

Tolvaptan vs Fluid Limits: Do Costs Outweigh pNa Gains?

Although tolvaptan bests fluid restriction at raising plasma sodium concentration, 19% of patients experience overcorrection ...
Nasdaq

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

“These Phase 2a data underscore our belief that SPN-820 has the potential as a novel treatment option for patients with depression, with the opportunity to decrease symptoms quickly and without ...
Managed Healthcare Executive

Vertex reports data showing opioid-free recovery with Journavx for most patients after plastic surgery

New phase 4 data from Vertex Pharmaceuticals revealed that more than 90% of patients recovering from aesthetic or reconstructive surgery remained opioid-free when treated with Journavx (suzetrigine) ...
Seeking Alpha

Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Atai Beckley BPL-003 phase IIb open-label extension ...
ascopubs.org

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or ...
Seeking Alpha

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year ...
The American Journal of Managed Care

Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study

Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...
Cure Today

Open-Label Extension of Ponsegromab Shows Efficacy in Cancer-Associated Cachexia

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...
Nasdaq

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...